VEGFA and Hypertension: Antineoplastic drugs designed to target vascular endothelial growth factor (VEGF) such as sunitinib, sorafenib, bevacizumab, and others, have been linked to the development of a syndrome characterized by severe hypertension and/or acute or chronic kidney injury, with or without proteinuria, and associated with histopathological evidence of TMA in the kidney [7, 8].